Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Position Lifted by Empowered Funds LLC

Empowered Funds LLC boosted its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) by 32.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 8,693 shares of the company's stock after purchasing an additional 2,130 shares during the quarter. Empowered Funds LLC's holdings in Medpace were worth $2,888,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Centaurus Financial Inc. increased its stake in Medpace by 2.0% during the third quarter. Centaurus Financial Inc. now owns 1,513 shares of the company's stock worth $505,000 after acquiring an additional 29 shares during the last quarter. Lindenwold Advisors INC increased its stake in Medpace by 1.6% during the third quarter. Lindenwold Advisors INC now owns 2,026 shares of the company's stock worth $676,000 after acquiring an additional 32 shares during the last quarter. M&T Bank Corp increased its stake in Medpace by 1.2% during the third quarter. M&T Bank Corp now owns 3,199 shares of the company's stock worth $1,068,000 after acquiring an additional 37 shares during the last quarter. Custom Index Systems LLC increased its stake in Medpace by 3.0% during the fourth quarter. Custom Index Systems LLC now owns 1,290 shares of the company's stock worth $429,000 after acquiring an additional 37 shares during the last quarter. Finally, Nations Financial Group Inc. IA ADV increased its stake in Medpace by 1.7% during the third quarter. Nations Financial Group Inc. IA ADV now owns 2,376 shares of the company's stock worth $793,000 after acquiring an additional 39 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Price Performance

MEDP traded down $2.24 on Monday, reaching $340.17. The company's stock had a trading volume of 299,085 shares, compared to its average volume of 208,882. The stock has a market cap of $10.57 billion, a price-to-earnings ratio of 29.79, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a 1 year low of $302.01 and a 1 year high of $459.77. The business's 50 day moving average is $343.50 and its 200 day moving average is $348.07.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts' consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. As a group, research analysts forecast that Medpace Holdings, Inc. will post 11.93 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently issued reports on MEDP. Baird R W lowered Medpace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, October 23rd. William Blair reiterated an "outperform" rating on shares of Medpace in a research note on Tuesday, October 22nd. TD Cowen lowered their target price on Medpace from $413.00 to $372.00 and set a "buy" rating for the company in a research note on Wednesday, October 23rd. Finally, Robert W. Baird increased their target price on Medpace from $354.00 to $362.00 and gave the company a "neutral" rating in a research note on Monday, January 27th. Seven research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.